Barr, Alastair J. (2010) Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Medicinal Chemistry, 2 (10). pp. 1563-1576. ISSN 1756-8919
Full text not available from this repository.
Several 'classical' protein tyrosine phosphatases are attractive therapeutic targets, including PTP1B for obesity and Type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis. Progress has been made in identifying a broad range of chemically distinct inhibitors; however, developing selective and cell-permeable clinically useful compounds has proved challenging. Here the ongoing challenges and recent significant advances in the field are reviewed. Key novel compounds are highlighted and a perspective on the future of phosphatase inhibitor development is presented.
|Research Community:||University of Westminster > Life Sciences, School of|
|Deposited On:||20 Jul 2012 15:59|
|Last Modified:||20 Jul 2012 15:59|
Repository Staff Only: item control page